Quality control of peptide pools in personalized cancer therapy



Peptide pools are versatile tools in the development of immunotherapeutic solutions. The quality of the peptide pools is crucial for the accuracy of immunotherapies, but the quality control of these complex products poses a significant challenge. Gaby Bosc-Bierne and team at the Federal Institute for Materials Research and Testing (BAM) and peptides&elephants, both in Berlin, Germany, evaluated the effectiveness of ultra-high performance liquid chromatography (UHPLC) coupled with two different detectors. [1] They used the peptide pool CEF advanced from peptides&elephants for this approach to establish a cost-efficient and swift quality control method for peptide pools in immunotherapy.   

Quality control of peptide pools poses a significant challenge due to their complex composition, which sometimes includes more than a hundred individual peptides. In order to expand tumor-specific T cells for immunotherapy, each of these peptides must be verified to be present in the peptide pool. Potential synthesis errors, degradation processes, adsorption losses, dimerizations, and other unwanted chemical changes must be rigorously excluded. Moreover, the pool must not contain any unintended peptides.

Advantages and disadvantages of peptide quantification methods

Peptide quantification is typically performed using (U)HPLC-UV, (U)HPLC-MS/MS, or capillary electrophoresis mass spectrometry (CE-MS). Each method has its advantages and disadvantages when it comes to quality control of peptide pools. HPLC-UV is not ideal for complex samples due to a frequent lack of baseline separation, and synthesis byproducts and degradation products can further complicate matters. (U)HPLC-MS/MS is more suited to complex samples, offering excellent selectivity and serving as the gold standard for quantification. It can also confirm the identity and indirectly the structure of the analytes. However, ionization efficiency can vary among compounds in mass spectrometric methods, and co-eluting substances can suppress ions in the ion source, leading to matrix effects that can make individual peptides unidentifiable. While reduction or compensation strategies can mitigate matrix effects, they may not be practical due to high calibration efforts or the use of expensive isotope-labeled analyte analogues. 

UHPLC with two different detectors

Given these challenges, there is a need to develop enhanced methods for peptide pool quality control. Bosc-Bierne and her team have explored the potential of employing ultra-high performance liquid chromatography (UHPLC) equipped with two different detectors for cost-effective and rapid quality control of peptide pools. They utilized a standard UV detector at 214 nm for quantitative analysis and a high-resolution mass spectrometer (HRMS) for identity confirmation, achieving quantification and identification in a single chromatographic run. The team conducted their investigations with the frequently used CEF advanced peptide pool from peptides&elephants, which contains 32 peptides from cytomegalovirus, Epstein-Barr virus, and influenza virus.

UHPLC-UV-HRMS

 

Separation protocol and overlapping peak areas

The findings of the study indicate that a flat gradient, increased temperature, and trifluoroacetic acid at a concentration of 0.05/0.04% were beneficial for the chromatographic separation of the peptide pool. Applying this optimized separation protocol, 30 out of the 32 peptides in the pool were relatively quantified using UHPLC-UV/HRMS. The remaining two peptides were identified by their masses but not quantified due to poor peak shape. Several peaks in the experimental setup overlapped significantly, making it difficult to determine UV peak areas. However, when using simple perpendicular drop integration, relative quantification was possible by grouping peaks. More computationally intensive peak fitting methods could be employed in the future as an alternative.

Efficient for medium sized peptide pools

In summary, the study demonstrates that cost-effective and time-efficient quality control of synthetic peptide pools is possible, when using UV detection for relative quantification and high-resolution mass spectrometry for peptide confirmation in just one chromatographic run. The proposed method significantly improves the quality control of peptide pools in immunotherapy, particularly for pools up to medium size.

Peptides&elephants is currently investigating whether the method is also suitable for larger peptide pools. In addition, the scientists are refining the method by utilizing more recent UHPLC systems with enhanced resolution and longer columns that allow for longer separation times to increase peak capacity. The implementation of chromatography optimization software and artificial intelligence are further advancements that could contribute to optimizing separation and integration methods, as well as analyzing complex mass spectra.

Literature

  1. Bosc-Bierne G, Ewald S, Kreuzer OJ, Weller MG. Efficient Quality Control of Peptide Pools by UHPLC and Simultaneous UV and HRMS Detection. Separations. 2024; 11(5):156. https://doi.org/10.3390/separations11050156
Skip product gallery

Related products

Tip
Actin Peptide Pool, human
The HUMAN (Actin) Peptide Pool consists of 92 overlapping peptides derived from a peptide scan through Actin, alpha skeletal muscle (UniProt ID: P68133) of Homo sapiens. The peptides are 15mers that overlap by 11 amino acids. One unit of HUMAN (Actin) Peptide Pool allows the stimulation of 2,5 x 108 cells. Actin is a ubiquitously expressed protein and therefore an excellent negative control for T cell assays. Relevant controls are critical for measuring antigen-specific responses as they allow accurate interpretation of test results. The HUMAN (Actin) Peptide Pool can rule out non-specific binding of peptides to the tested T cells, while a negative control with medium detects general background signals. Examples of publications where actin was used as a negative control: Baker FL, et al.: Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2. Brain Behav Immun Health. 2023 Mar;28:100600. doi: 10.1016/j.bbih.2023.100600. Sweeney, E et al.: Photothermal Prussian blue nanoparticles generate potent multi‐targeted tumor‐specific T cells as an adoptive cell therapy. Bioeng Transl Med. 2023;e10639. doi.org/10.1002/btm2.10639. Roy, P et al.: Immunodominant MHC-II (Major Histocompatibility Complex II) Restricted Epitopes in Human Apolipoprotein B. Circ Res. 2022 Jul 22;131(3):258-276. doi: 10.1161/CIRCRESAHA.122.321116. Lasagna, Angioletta et al. “The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy.”Human vaccines & immunotherapeutics vol. 19,3 (2023): 2288282. doi:10.1080/21645515.2023.2288282

€237.50*
AFP Peptide Pool, human
Pool of 150 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Alpha-fetoprotein (Swiss-Prot ID: P02771) of Homo sapiens for T cell assays (e.g. ELISPOT). One unit allows the stimulation of 2,5 x 108 cells.

€380.70*
Alpha Variant B.1.1.7 SCoV2 (Spike Glycoprotein) Peptide Pool
This peptide pool with 31 peptides covers all mutations in the Spike Glycoprotein derived from the alpha variant B.1.1.7 of SARS-CoV-2 which emerged in Britain in December 2020 and is thought to be roughly 50 percent more infectious and now dominant in the U.S. One unit allows the stimulation of 2,5 x 108 cells.

€316.90*
Alpha-crystallin B chain Peptide Pool, human
Pool of 41 peptides derived from a peptide scan (15mers with 11 aa overlap) through Alpha-crystallin B chain protein (Uni-Prot ID P02511) of Homo sapiens (Human). One unit allows the stimulation of 2,5 x 108 cells.

€237.50*
Tip
Aquaporin-4 Peptide Pool, human
Pool of 78 peptides derived from a peptide scan (15mers with 11 aa overlap) through Aquaporin-4 protein (Uni-Prot ID P55087) of Homo sapiens (Human). One unit allows the stimulation of 2,5 x 108 cells.

€237.50*
Tip
BA.4/BA.5 Omicron full length SCoV2 (Spike Glycoprotein) Peptide Pool
BA.4/BA.5 Omicron peptide pool covers the whole spike glycoprotein with all mutations of the new omicron variants BA4 and BA.5 of SARS-CoV-2 (315 peptides, delivered in two subpools of 158 & 157 peptides). One unit allows the stimulation of 2,5 x 108 cells.

€887.50*
Beta Variant B.1.351 SCoV2 (Spike Glycoprotein) Peptide Pool
This peptide pool with 34 peptides covers all mutations in the Spike Glycoprotein derived from the beta variant B.1.351 of SARS-CoV-2 which emerged in South Africa in December 2020 and reduces the effectiveness of some vaccines. One unit allows the stimulation of 2,5 x 108 cells.

€316.90*
BKV (BK-Virus LT) Peptide Pool
Peptide pool of 171 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Large T antigen (UniProtKB - P03071) of BK polyomavirus for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€380.70*
BKV VP1 Peptide Pool
Peptide pool of 88 peptides derived from a peptide scan (15mers with 11 aa overlap) through Major capsid protein VP1 (UniProt ID: P14996) from BK polyomavirus (human). One unit allows the stimulation of 2,5 x 108 cells.

€301.30*
CEF (classic) Peptide Pool (>95% HPLC)
The CEF peptide pool is a lyophilized mixture of 23 peptides from cytomegalovirus (CMV), Epstein-Barr virus (EBV), and influenza virus. It consists of defined HLA class I-restricted T cell epitopes from these three viruses. The CEF peptide pool is used as a positive control to stimulate T cells. It induces secretion of e.g., IFN-γ, IL-2, and granzyme B from human CD8 T cells. The peptides of this product are supplied as trifluoracetate salts. One unit allows the stimulation of 2,5 x 108 cells.

€126.30*
CEF control Peptide Pool (>95% HPLC, advanced)
The CEF peptide pool is a lyophilized mixture of 32 peptides from cytomegalovirus (CMV), Epstein-Barr virus (EBV), and influenza virus. It consists of defined HLA class I-restricted T cell epitopes from these three viruses, and can be used as a positive control to stimulate T cells. The CEF peptide pool is used as a positive control to stimulate T cells. It induces secretion of e.g., IFN-γ, IL-2, and granzyme B from human CD8 T cells. One unit allows the stimulation of 2,5 x 108 cells.These are sequence, source and corresponding MHC class I molecule of each peptide: Sequence Source MHC class I molecule H-VSDGGPNLY-OH Influenza A HLA-A1 H-CTELKLSDY-OH Influenza A HLA-A1 H-GILGFVFTL-OH Influenza M HLA-A2 H-FMYSDFHFI-OH Influenza A HLA-A2 H-CLGGLLTMV-OH EBV LMP2A HLA-A2 H-GLCTLVAML-OH EBV BMLF1 HLA-A2 H-NLVPMVATV-OH HCMV pp65 HLA-A2 H-KTGGPIYKR-OH Influenza NP HLA-A68 H-RVLSFIKGTK-OH Influenza NP HLA-A3 H-ILRGSVAHK-OH Influenza A HLA-A3 H-RVRAYTYSK-OH EBV HLA-A3 H-RLRAEAQVK-OH EBV HLA-A3 H-SIIPSGPLK-OH Influenza M HLA-A3/A11/A6 H-AVFDRKSDAK-OH EBV EBNA 4NP HLA-A11 H-IVTDFSVIK-OH EBV HLA-A11 H-ATIGTAMYK-OH EBV HLA-A11 H-DYCNVLNKEF-OH EBV RTA HLA-A24 H-LPFDKTTVM-OH Influenza NP HLA-B7 H-RPPIFIRRL-OH EBV  HLA-B7 H-ELRSRYWAI-OH   Influenza NP HLA-B8 H-RAKFKQLL-OH   EBV B2LF-1 HLA-B8 H-FLRGRAYGL-OH   EBV EBNA 3A HLA-B8 H-QAKWRLQTL-OH   EBV EBNA 3 HLA-B8 H-SDEEEAIVAYTL-OH   HCMV HLA-B18 H-SRYWAIRTR-OH   Influenza NP HLA-B27 H-ASCMGLIY-OH  Influenza A  HLA-B27 H-RRIYDLIEL-OH   EBV EBNA 3C HLA-B27 H-YPLHEQHGM-OH  EBV EBNA 3A  HLA-B35 H-IPSINVHHY-OH   CMV pp65 HLA-B35 H-EENLLDFVRF-OH   EBV HLA-B44 H-EFFWDANDIY-OH  HCMV  HLA-B44 H-TPRVTGGGAM-OH   HCMV HLA-B7 For more information and application examples, read our blog posts: "Esophagogastric adenocarcinoma: Tumor-associated antigens, immune responses and HLA-I expression" "Quality control of peptide pools in personalized cancer therapy"

€151.30*
CEP55 Peptide Pool, human
Pool of 114 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Centrosomal Protein 55 (Swiss-Prot ID: Q53EZ4) for T cell assays (e.g. ELISPOT). One unit allows the stimulation of 2,5 x 108 cells.You can find applications and references in our blog post: Esophagogastric adenocarcinoma: Tumor-associated antigens, immune responses and HLA-I Expression

€316.90*
CMV Sub Peptide Pool (>95% HPLC)
This peptide pool consists of 14 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from cytomegalovirus (CMV).

€138.20*
Tip
Coagulation factor VIII, human Peptide Pool
Pool of 585 peptides (delivered in three sub pools with 195 peptides each) derived from a peptide scan (15mers with 11 aa overlap) through Coagulation factor VIII protein (Uni-Prot ID P00451) of Homo sapiens (Human). One unit allows the stimulation of 2,5 x 108 cells.

€967.50*
crf1 Peptide Pool
Pool of 96 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Probable glycosidase crf1 (UniProt ID: Q8J0P4) of Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) (Aspergillus fumigatus) One unit allows the stimulation of 2,5 x 108 cells.

€237.50*
Only 8 available
CT45A1 Peptide Pool, human
Pool of 45 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through cancer/testis antigen family 45 member A1 (Uniprot ID: Q5HYN5) of Homo sapiens (Human) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€206.30*
CT83/KKLC1 Peptide Pool, human
Pool of 26 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Kita-kyushu lung cancer antigen 1 (UniProtID: Q5H943) of Homo sapiens (Human) for T cell assays (e.g. ELISPOT). One unit allows the stimulation of 2,5 x 108 cells.You can find applications and references in our blog post: Esophagogastric adenocarcinoma: Tumor-associated antigens, immune responses and HLA-I Expression

€237.50*
Tip
Delta Variant B.1.617.2 SCoV2 (Spike Glycoprotein) Peptide Pool
This peptide pool with 27 peptides covers all mutations in the Spike Glycoprotein derived from the delta variant B.1.617.2 of SARS-CoV-2 which is prevalent in India and carries the L452R spike mutation, among others. One unit allows the stimulation of 2,5 x 108 cells.

€316.90*
Delta Variant B.1.617.2 SCoV2 wt (Spike Glycoprotein) Peptide Pool
This peptide pool consists of 27 peptides of the spike protein and represent the wildtype peptides to the mutations of the delta variant of SARS-CoV-2 (B.1.617.2) and is therefore recommended as a reference. One unit allows the stimulation of 2,5 x 108 cells.

€316.90*
EBV (BZLF1) Peptide Pool
Peptide pool of 59 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Trans-activator protein BZLF1 (UniProt ID: P03206) of Epstein-Barr virus (HHV4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€277.50*
EBV (EBNA-3a) Peptide Pool
The EBV (EBNA-3a) Peptide Pool from peptides&elephants is designed for in vitro T cell stimulation and epitope analysis in research on Epstein-Barr virus (EBV, HHV-4). This pool contains 234 synthetic 15-mer peptides, overlapping by 11 amino acids, and spans the complete sequence of EBNA-3a (Epstein-Barr nuclear antigen 3a; UniProt ID: P12977). Each unit enables the stimulation of up to 2.5 × 10⁸ peripheral blood mononuclear cells (PBMCs) and is ideal for use in ELISpot, intracellular cytokine staining (ICS), and flow cytometry-based T cell assays. Scientific Background EBV is a ubiquitous herpesvirus that infects more than 90% of the global population. It is the causative agent of infectious mononucleosis and is closely associated with several B cell malignancies, including post-transplant lymphoproliferative disease (PTLD), diffuse large B cell lymphoma (DLBCL), Burkitt lymphoma, and Hodgkin lymphoma. During latency, EBV can enter different gene expression programs. Latency type III, in which all nine latent proteins are expressed, is the only form capable of transforming B cells in vitro, resulting in lymphoblastoid cell lines (LCLs). Among these latency proteins, EBNA-3a plays a supportive but non-essential role in B cell transformation: EBV mutants lacking EBNA-3a can still transform B cells, but with significantly reduced efficiency. EBNA-3a–deficient LCLs proliferate more slowly and show increased apoptosis compared to wild-type virus–derived LCLs. EBNA-3a appears to regulate a subset of cellular genes, some of which overlap with those regulated by EBNA2. The two proteins can act antagonistically or cooperatively to control gene expression. These findings position EBNA-3a as a key modulator of B cell proliferation and survival during EBV latency, and as a relevant CD8⁺ T cell target in both basic immunological studies and translational research.

€301.30*
EBV (EBNA-3b) Peptide Pool
Peptide pool of 234 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Epstein-Barr nuclear antigen 4 (EBNA3b) (UniProt ID: Q1HVG4) of Epstein-Barr virus (HHV4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€301.30*
EBV (GP350/GP340) Peptide Pool
Peptide pool of 224 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Envelope glycoprotein GP350/GP340 (UniProt ID: P03200) of Epstein-Barr virus (EBV, Humanes Herpesvirus 4, HHV4). One unit allows the stimulation of 2,5 x 108 cells. gp350/gp340 versus gp350/220 The EBV envelope glycoprotein gp350/gp340 (or gp350/220) is encoded by the BLLF1 gene and represents one of the most abundant surface proteins of the virion. The protein exists in multiple isoforms generated by alternative splicing. While gp350 denotes the full-length form, gp340 and gp220 refer to truncated isoforms of the same glycoprotein, which retain identical biological function. Differences in naming (gp340 vs. gp220) arise from historical nomenclature, experimental detection methods, and variations in glycosylation state.  Initial attachment and endocytosis Gp350/gp340 belongs to the core set of EBV glycoproteins that define viral tropism and host cell interaction – together with gp42, BMRF2, gH/gL, and gB. Gp350/gp340 plays a central role in viral attachment and entry into B lymphocytes. Through molecular mimicry of complement components, gp350/gp340 specifically recognizes complement receptor 1 (CR1/CD35) and complement receptor 2 (CR2/CD21) on B cells. This interaction mediates the initial attachment of EBV particles and triggers endocytosis of the immobilized virion, marking the first step of EBV infection in B lymphocytes. Major target of immune responses Due to its surface exposure, high abundance, and essential role in viral entry, gp350/gp340 represents a major target of humoral and cellular immune responses. Peptides derived from gp350/gp340 are widely used to study EBV-specific T cell immunity, epitope recognition, and immune monitoring in the context of EBV infection, EBV-associated malignancies, and vaccine development. The EBV (gp350/gp340) Peptide Pool from peptides&elephants provides comprehensive sequence coverage of this key viral glycoprotein and is ideally suited for applications such as T cell stimulation assays, epitope mapping, and immunological profiling in EBV research.

€301.30*
EBV (LMP1) Peptide Pool
Peptide pool of 94 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Latent membrane protein 1 (LMP1) (UniProt ID: P03230) of Epstein-Barr virus (HHV4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€333.20*
EBV (LMP2) Peptide Pool
The EBV (LMP2) Peptide Pool from peptides&elephants is designed for advanced T cell stimulation and epitope mapping in immunological studies of Epstein-Barr virus (EBV, HHV-4). This peptide pool consists of 122 synthetic 15-mer peptides, overlapping by 11 amino acids, and covers the full sequence of the Latent Membrane Protein 2 (LMP2) (UniProt ID: P13285). LMP2 is a latency-associated antigen commonly expressed in EBV-related malignancies such as nasopharyngeal carcinoma and Hodgkin’s lymphoma. It is a known target of both CD4⁺ and CD8⁺ T cell responses. Each unit of the peptide pool allows for the stimulation of up to 2.5 × 10⁸ peripheral blood mononuclear cells (PBMCs) and is optimized for use in T cell assays, such as ELISpot, intracellular cytokine staining (ICS), and flow cytometry-based functional readouts. Scientific Background LMP2 is one of the most clinically relevant antigens for therapeutic EBV vaccine development, particularly in the context of EBV-associated cancers such as nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disease (PTLD). Therapeutic vaccine candidates using viral vectors encoding LMP2 have successfully induced virus-specific CD8⁺ T cell responses in early-phase clinical trials. Furthermore, adoptive T cell therapies like posoleucel also target LMP2 alongside other latency proteins such as EBNA1, reinforcing its significance as a conserved and immunodominant antigen. This peptide pool is an ideal tool for: Characterizing patient-specific or vaccine-induced T cell responses Ex vivo stimulation of EBV-specific T cells Epitope screening and immune profiling Immune monitoring in clinical trials of EBV-targeted vaccines or adoptive T cell therapies

€340.70*